Clinical trial

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

NCT07332156

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention SGLT2 inhibitor Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Sulfonylureas (SU) Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention DPP4 inhibitors Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-01-01

PhaseN/A

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

COPD (Chronic Obstructive Pulmonary Disease)candidate · MONDO: chronic obstructive pulmonary disease

Lung Cancer (Diagnosis)unresolved

Interventions

SGLT2 inhibitorDRUG

Sulfonylureas (SU)DRUG

DPP4 inhibitorsDRUG

Sponsors & collaborators

Samsung Medical Centerlead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07332156 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.